---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact. 1 evidence topic quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary/budget-impact"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Ersodetug

<a id="topic-1.1.3-1"></a>

### Summary

- Ersodetug is investigational and has no published price, and no budget impact model, cost-effectiveness analysis, or health technology assessment of ersodetug has been published.
- The manufacturer estimates the U.S. eligible population at approximately 3,000 or approximately 4,000 patients per year (incidence) and about 2,500 malignant insulinoma plus about 1,500 NICTH patients (point-in-time prevalence as of October 2026), and assumes 9 vials per infusion and 117 vials per patient per year at the 9 mg/kg maintenance dose.
- In the manufacturer's claims data, the primary payer was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%. Its payer research anticipates prior authorization with a step through diazoxide for insulinoma and reimbursement through a J-code.

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
